4.5 Review

Targeting the Notch signaling pathway in autoimmune diseases

Journal

EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 14, Issue 5, Pages 553-565

Publisher

INFORMA HEALTHCARE
DOI: 10.1517/14728221003752750

Keywords

autoimmune diseases; GSIs; Notch signaling pathway; therapeutic perspectives

Funding

  1. National Natural Science Foundation [30600680, 30770922, 30600259, 30628015]
  2. 973 Project [2006CB503800]
  3. Chinese Ministry of Health [2007-2009]
  4. National Public Fare [200802031]
  5. Shandong Technological Development [2005BS03022, BS2009SW014, Q2008C07, 2005GG4202018]
  6. Taishan Scholar Fundation
  7. SRF for ROCS of SEM
  8. IIFSDU [2009TS063]

Ask authors/readers for more resources

Areas covered in this review: The role of the Notch pathway and therapeutic strategies targeting it in many illnesses, especially autoimmune diseases. What the reader will gain: The Notch pathway has unique and attractive advantages for targeting. Targeting it has already been trialed in many experiments, which may show better efficacy and fewer side effects compared with classical drugs for the treatment. Targeting Notch might provide etiological rather than symptomatic treatment. Take home message: Various methods targeting the Notch pathway have been under investigation. Rational targeting of the Notch signaling pathway in cancer and some autoimmune diseases has proven to be successful. Classical drugs for the treatment of autoimmune diseases are inefficient and toxic to some extent, and targeting the Notch pathway is a promising therapeutic concept. However, there are still many questions about targeting Notch in autoimmune diseases, and further investigation will be needed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available